SmithKline Beecham stops proton pump development
Phase III clinical trials of the irreversible proton pump inhibitor pantoprazole (formerly designated SK&F-96022) have been halted in the U.K. and Europe, the company confirms Nov. 27. The drug was in Phase II in the U.S. SB says it "will not continue with [pantoprazole's] development" but notes that it has several follow-on compounds in preclinicals and early clinicals, including SK&F 96067 and SK&F 97574. SB stopped the studies after results of a preliminary analysis of a two-year rate carcinogenicity study showed "an increased incidence of hepatocellular neoplasia at doses of 50 mg/kg/day and 200 mg/kg/day," doses greater than those used in human clinicals. Pantoprazole was being co-developed by SB and Byk Gulden, which is continuing development of the drug, SB says. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth